Most importantly, additional evidence suggests that alterations in the expression level of RBM3 could be associated with advanced pathological tumor stages in lung carcinoma or with aggressive features in esophageal, colorectal or breast cancer [60,61,62,63], which reinforces the crucial role of this factor in tumor pathologies. Here, RBM3 is linked to lung carcinoma.